Cognitive remission: a novel objective for the treatment of major depression?

Aerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health Treatment. Front Hum Neurosci (2016) 0.78

Piromelatine ameliorates memory deficits associated with chronic mild stress-induced anhedonia in rats. Psychopharmacology (Berl) (2016) 0.76

Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study. Biol Psychiatry Cogn Neurosci Neuroimaging (2017) 0.75

The 'cognitive footprint' of psychiatric and neurological conditions: cross-sectional study in the UK Biobank cohort. Acta Psychiatr Scand (2017) 0.75

Methylene blue and its analogues as antidepressant compounds. Metab Brain Dis (2017) 0.75

Antidepressant pharmacotherapy in old-age depression-a review and clinical approach. Eur J Clin Pharmacol (2017) 0.75

A new depression scale designed to be sensitive to change. Br J Psychiatry (1979) 36.40

Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol (1967) 22.39

The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry (2003) 7.19

Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol (2004) 3.67

Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. Eur Neuropsychopharmacol (2015) 3.46

Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun (2010) 3.37

Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry (2001) 3.07

Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry (2006) 2.68

Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull (2012) 2.65

The epidemiology of depression across cultures. Annu Rev Public Health (2013) 2.60

No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr (2007) 2.57

Reducing suicidal ideation and depression in older primary care patients: 24-month outcomes of the PROSPECT study. Am J Psychiatry (2009) 2.56

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44

Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev (2008) 2.30

Job performance deficits due to depression. Am J Psychiatry (2006) 2.09

A meta-analysis of depression severity and cognitive function. J Affect Disord (2009) 1.94

A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry (2006) 1.90

Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci (2008) 1.88

Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry (2000) 1.78

Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry (2007) 1.78

The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta (2013) 1.72

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol (2012) 1.71

Effects of major depression on moment-in-time work performance. Am J Psychiatry (2004) 1.70

Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry (2004) 1.70

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry (2009) 1.64

A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. J Affect Disord (2011) 1.58

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem (2011) 1.56

Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol (2014) 1.52

Association between depression severity and neurocognitive function in major depressive disorder: a review and synthesis. Neuropsychology (2010) 1.52

Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci (2008) 1.48

Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety (2013) 1.48

Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology (2004) 1.48

Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders. Biol Psychiatry (2014) 1.46

Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res (2006) 1.39

Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord (2000) 1.39

Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol (2013) 1.36

S-Adenosyl-L-methionine (SAMe): from the bench to the bedside--molecular basis of a pleiotrophic molecule. Am J Clin Nutr (2002) 1.33

Functions of coenzyme Q10 in inflammation and gene expression. Biofactors (2008) 1.32

Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One (2014) 1.32

Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med (2013) 1.31

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol (2014) 1.30

Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord (2010) 1.29

Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology (2012) 1.24

Evidence for continuing neuropsychological impairments in depression. J Affect Disord (2004) 1.23

Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev (2015) 1.21

Glutamatergic modulation of auditory information processing in the human brain. Biol Psychiatry (2011) 1.20

Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders? Neuropharmacology (2012) 1.19

Cognitive dysfunction in unipolar depression: implications for treatment. J Affect Disord (2013) 1.18

Omega-3 polyunsaturated fatty acid supplementation confers long-term neuroprotection against neonatal hypoxic-ischemic brain injury through anti-inflammatory actions. Stroke (2010) 1.18

Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology (2001) 1.17

The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials. J Clin Psychiatry (2008) 1.17

Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep (2009) 1.16

Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci Biobehav Rev (2011) 1.16

Neurocognitive correlates of response to treatment in late-life depression. Am J Geriatr Psychiatry (2008) 1.15

Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med (2012) 1.13

Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry (2006) 1.12

Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab (2011) 1.09

Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis. Psychol Med (2008) 1.08

Successful computer-assisted cognitive remediation therapy in patients with unipolar depression: a proof of principle study. Psychol Med (2007) 1.08

A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol (2004) 1.08

Longitudinal assessment of neuropsychological function in major depression. Aust N Z J Psychiatry (2009) 1.08

Executive function improvement upon remission of recurrent unipolar depression. Eur Arch Psychiatry Clin Neurosci (2005) 1.07

Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology (2011) 1.07

New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology (2012) 1.06

Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry (2012) 1.05

The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med (2012) 1.05

A 35-year longitudinal assessment of cognition and midlife depression symptoms: the Vietnam Era Twin Study of Aging. Am J Geriatr Psychiatry (2011) 1.04

The empirical redefinition of the psychometric criteria for remission in bipolar disorder. J Affect Disord (2007) 1.04

Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry (2012) 1.04

Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol (2003) 1.04

Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm (Vienna) (2008) 1.03

Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res (2009) 1.02

Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage. Brain Res (2005) 1.01

Mediators of the association between depression and role functioning. Acta Psychiatr Scand (2008) 1.00

Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. J Neuroimmunol (2014) 1.00

Amelioration of acute sequelae of blast induced mild traumatic brain injury by N-acetyl cysteine: a double-blind, placebo controlled study. PLoS One (2013) 1.00

A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr Scand (2011) 0.99

Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr (2013) 0.99

Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord (2011) 0.98

Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exp Brain Res (2007) 0.97

Cognitive training in affective disorders improves memory: a preliminary study using the NEAR approach. J Affect Disord (2009) 0.96

Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl (2000) 0.96

Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology (2012) 0.96

Biology and therapeutic applications of peroxisome proliferator- activated receptors. Curr Top Med Chem (2012) 0.95

Relationship between markers of insulin resistance, markers of adiposity, HbA1c, and cognitive functions in a middle-aged population-based sample: the MONA LISA study. Diabetes Care (2012) 0.95

The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med (2015) 0.94

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology (2015) 0.94

Minocycline attenuates cognitive impairment induced by isoflurane anesthesia in aged rats. PLoS One (2013) 0.94

The relationship between neurocognitive and psychosocial functioning in major depressive disorder: a systematic review. J Clin Psychiatry (2014) 0.93

The depression-executive dysfunction (DED) syndrome and response to antidepressants: a meta-analytic review. Int J Geriatr Psychiatry (2010) 0.93

The societal cost of depression: evidence from 10,000 Swedish patients in psychiatric care. J Affect Disord (2013) 0.92

Persistent non-verbal memory impairment in remitted major depression - caused by encoding deficits? J Affect Disord (2009) 0.92

Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depress Anxiety (2005) 0.92

Minocycline: therapeutic potential in psychiatry. CNS Drugs (2012) 0.92

Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat (2007) 0.92

A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. J Alzheimers Dis (2014) 0.91

Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol Psychiatry (2014) 0.91

Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology (2012) 0.91

Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology (2012) 0.91

Effects of curcumin on learning and memory deficits, BDNF, and ERK protein expression in rats exposed to chronic unpredictable stress. Behav Brain Res (2014) 0.90

Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses. Neuropsychiatr Dis Treat (2015) 0.82

Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology (2013) 0.81